Cargando…

Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy

BACKGROUND: The helix-loop-helix transcription factor Id-1 (an inhibitor of differentiation and DNA binding) plays a role in development and progression of many tumours. Id-1 is known to exert its effects on the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Meteoglu, Ibrahim, Meydan, Nezih, Erkus, Muhan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588562/
https://www.ncbi.nlm.nih.gov/pubmed/19014499
http://dx.doi.org/10.1186/1756-9966-27-69
_version_ 1782160952515362816
author Meteoglu, Ibrahim
Meydan, Nezih
Erkus, Muhan
author_facet Meteoglu, Ibrahim
Meydan, Nezih
Erkus, Muhan
author_sort Meteoglu, Ibrahim
collection PubMed
description BACKGROUND: The helix-loop-helix transcription factor Id-1 (an inhibitor of differentiation and DNA binding) plays a role in development and progression of many tumours. Id-1 is known to exert its effects on the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF). The aim of this study was to reveal whether there was a relationship between Id-1 and EGFR and VEGF in colorectal carcinoma. METHODS: Tumour and non-tumour tissue specimens from 46 cases of colorectal carcinoma were exposed to immunohistochemical staining for Id-1, EGFR and VEGF. The relationship between the degree of staining and tumour grade, tumour stage and all tumour markers was investigated. RESULTS: Tumour cells showed positive staining for Id-1 in 43 cases (93.5%), for EGFR in 41 cases (89%) and for VEGF in 42 cases (91%). There was a significant relation between the tumour grade and the degree of staining for Id-1, EGFR and VEGF. The relation between the tumour stage and the degree of staining for Id-1, EGFR and VEGF was also significant. There was a significant relation between Id-1 expression and EGFR and VEGF expressions. Non-tumoural tissue specimens were not stained with Id-1 and EGFR antibodies in any of the cases, but stained with VEGF antibody in 3 cases. CONCLUSION: This study revealed that Id-1, EGFR and VEGF took part in development and progression of colorectal carcinomas and that Id-1 was associated with regulations of EGFR and VEGF. The results of this study support the idea that not only EGFR and VEGF but also Id-1 could be new targets in cancer treatment.
format Text
id pubmed-2588562
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25885622008-11-28 Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy Meteoglu, Ibrahim Meydan, Nezih Erkus, Muhan J Exp Clin Cancer Res Research BACKGROUND: The helix-loop-helix transcription factor Id-1 (an inhibitor of differentiation and DNA binding) plays a role in development and progression of many tumours. Id-1 is known to exert its effects on the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF). The aim of this study was to reveal whether there was a relationship between Id-1 and EGFR and VEGF in colorectal carcinoma. METHODS: Tumour and non-tumour tissue specimens from 46 cases of colorectal carcinoma were exposed to immunohistochemical staining for Id-1, EGFR and VEGF. The relationship between the degree of staining and tumour grade, tumour stage and all tumour markers was investigated. RESULTS: Tumour cells showed positive staining for Id-1 in 43 cases (93.5%), for EGFR in 41 cases (89%) and for VEGF in 42 cases (91%). There was a significant relation between the tumour grade and the degree of staining for Id-1, EGFR and VEGF. The relation between the tumour stage and the degree of staining for Id-1, EGFR and VEGF was also significant. There was a significant relation between Id-1 expression and EGFR and VEGF expressions. Non-tumoural tissue specimens were not stained with Id-1 and EGFR antibodies in any of the cases, but stained with VEGF antibody in 3 cases. CONCLUSION: This study revealed that Id-1, EGFR and VEGF took part in development and progression of colorectal carcinomas and that Id-1 was associated with regulations of EGFR and VEGF. The results of this study support the idea that not only EGFR and VEGF but also Id-1 could be new targets in cancer treatment. BioMed Central 2008-11-12 /pmc/articles/PMC2588562/ /pubmed/19014499 http://dx.doi.org/10.1186/1756-9966-27-69 Text en Copyright © 2008 Meteoglu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Meteoglu, Ibrahim
Meydan, Nezih
Erkus, Muhan
Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
title Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
title_full Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
title_fullStr Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
title_full_unstemmed Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
title_short Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
title_sort id-1: regulator of egfr and vegf and potential target for colorectal cancer therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588562/
https://www.ncbi.nlm.nih.gov/pubmed/19014499
http://dx.doi.org/10.1186/1756-9966-27-69
work_keys_str_mv AT meteogluibrahim id1regulatorofegfrandvegfandpotentialtargetforcolorectalcancertherapy
AT meydannezih id1regulatorofegfrandvegfandpotentialtargetforcolorectalcancertherapy
AT erkusmuhan id1regulatorofegfrandvegfandpotentialtargetforcolorectalcancertherapy